公开(公告)号：US20240207224A1

公开(公告)日：2024-06-27

申请号：US18509403

申请日：2023-11-15

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Jiajun Zhang ,  Xuri Gao ,  Hui Cao ,  Yuk Ming Siu ,  Bin Wang ,  Jiang Long ,  Wei Li ,  Matthew C. Rhodes ,  Xuechao Xing ,  Scott Mitchell ,  Yat Sun Or

IPC: A61K31/395 ,  A61K31/4192 ,  A61K31/4995 ,  A61P31/14 ,  C07D225/04 ,  C07D245/04 ,  C07D255/04 ,  C07D273/02 ,  C07D281/00 ,  C07D285/00 ,  C07D487/08

CPC classification number: A61K31/395 ,  A61K31/4192 ,  A61K31/4995 ,  A61P31/14 ,  C07D225/04 ,  C07D245/04 ,  C07D255/04 ,  C07D273/02 ,  C07D281/00 ,  C07D285/00 ,  C07D487/08

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230203048A1

公开(公告)日：2023-06-29

申请号：US17983474

申请日：2022-11-09

Applicant: ENANTA PHARMACEUTICALS, INC

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Xuechao Xing ,  Yong He ,  Matthew C. Rhodes ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14

CPC classification number: C07D487/10 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:





which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11919910B2

公开(公告)日：2024-03-05

申请号：US17983474

申请日：2022-11-09

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Xuechao Xing ,  Yong He ,  Matthew C. Rhodes ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14

CPC classification number: C07D487/10 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230331734A1

公开(公告)日：2023-10-19

申请号：US18130641

申请日：2023-04-04

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Hui Cao ,  Jiajun Zhang ,  Xuechao Xing ,  Matthew C. Rhodes ,  Xuri Gao ,  Wei Li ,  Yat Sun Or

IPC: C07D487/10

CPC classification number: C07D487/10

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit picornavirus, norovirus or coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a virus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230122228A1

公开(公告)日：2023-04-20

申请号：US17720603

申请日：2022-04-14

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Ruichao Shen ,  Yong He ,  Xuechao Xing ,  Matthew C. Rhodes ,  Joseph D. Panarese ,  Samuel Bartlett ,  Wei Li ,  Hui Cao ,  Jiajun Zhang ,  Xiaowen Peng ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14 ,  A61P11/00 ,  A61K9/00

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12145942B2

公开(公告)日：2024-11-19

申请号：US18130641

申请日：2023-04-04

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Hui Cao ,  Jiajun Zhang ,  Xuechao Xing ,  Matthew C. Rhodes ,  Xuri Gao ,  Wei Li ,  Yat Sun Or

IPC: C07D487/10

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit picornavirus, norovirus or coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a virus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11325916B1

公开(公告)日：2022-05-10

申请号：US17479248

申请日：2021-09-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Ruichao Shen ,  Yong He ,  Xuechao Xing ,  Matthew C. Rhodes ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14 ,  A61K31/404

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.